CA3261913A1 - THERAPEUTIC USE OF FIBROBLASTS TO STIMULATE THE IMMUNE SYSTEM - Google Patents
THERAPEUTIC USE OF FIBROBLASTS TO STIMULATE THE IMMUNE SYSTEMInfo
- Publication number
- CA3261913A1 CA3261913A1 CA3261913A CA3261913A CA3261913A1 CA 3261913 A1 CA3261913 A1 CA 3261913A1 CA 3261913 A CA3261913 A CA 3261913A CA 3261913 A CA3261913 A CA 3261913A CA 3261913 A1 CA3261913 A1 CA 3261913A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- activated
- fibroblasts
- fibroblast
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263305973P | 2022-02-02 | 2022-02-02 | |
| US63/305,973 | 2022-02-02 | ||
| US202263383499P | 2022-11-13 | 2022-11-13 | |
| US63/383,499 | 2022-11-13 | ||
| PCT/US2023/061809 WO2023150590A2 (en) | 2022-02-02 | 2023-02-02 | Therapeutic use of fibroblasts to stimulate the immune system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3261913A1 true CA3261913A1 (en) | 2023-08-10 |
Family
ID=87553049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3261913A Pending CA3261913A1 (en) | 2022-02-02 | 2023-02-02 | THERAPEUTIC USE OF FIBROBLASTS TO STIMULATE THE IMMUNE SYSTEM |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250090594A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4472644A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025505589A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023215314A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3261913A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023150590A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025264574A1 (en) * | 2024-06-17 | 2025-12-26 | Fibrobiologics, Inc. | Injectable thymus organoids |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6338953B1 (en) * | 1996-09-11 | 2002-01-15 | The General Hospital Corporation | Expression of an exogenous gene in a mammalian cell by use of a non-mammalian DNA virus having an altered coat protein |
| US20080279812A1 (en) * | 2003-12-05 | 2008-11-13 | Norwood Immunology, Ltd. | Disease Prevention and Vaccination Prior to Thymic Reactivation |
| US20100178700A1 (en) * | 2007-05-03 | 2010-07-15 | Australian Stem Cell Centre Ltd. | Novel thymic cellular populations and uses thereof |
-
2023
- 2023-02-02 EP EP23750375.0A patent/EP4472644A4/en active Pending
- 2023-02-02 AU AU2023215314A patent/AU2023215314A1/en active Pending
- 2023-02-02 WO PCT/US2023/061809 patent/WO2023150590A2/en not_active Ceased
- 2023-02-02 CA CA3261913A patent/CA3261913A1/en active Pending
- 2023-02-02 US US18/832,853 patent/US20250090594A1/en active Pending
- 2023-02-02 JP JP2024546022A patent/JP2025505589A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023150590A2 (en) | 2023-08-10 |
| WO2023150590A3 (en) | 2023-09-07 |
| JP2025505589A (ja) | 2025-02-28 |
| EP4472644A2 (en) | 2024-12-11 |
| EP4472644A4 (en) | 2026-02-25 |
| AU2023215314A1 (en) | 2024-08-15 |
| US20250090594A1 (en) | 2025-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240173354A1 (en) | Methods of inhibiting aging and treating aging-related disorders | |
| AU2001238695B2 (en) | Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof | |
| JP6971574B2 (ja) | 合成メッセンジャーrnaによるヒト人工多能性幹細胞のフィーダーフリー誘導 | |
| US12116592B2 (en) | Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (VSELs) | |
| KR20190007040A (ko) | 간엽 줄기 세포 및 근육 손상 및 근육-관련된 질환의 치료를 위한 이의 용도 | |
| AU2001238695A1 (en) | Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof | |
| WO2008063675A2 (en) | Endodermal progenitor cells | |
| TW202330910A (zh) | T細胞的製造方法 | |
| JP2024516172A (ja) | 間葉系前駆体又は幹細胞を使用する急性呼吸窮迫症候群(ards)を治療するための方法 | |
| AU2023215314A1 (en) | Therapeutic use of fibroblasts to stimulate the immune system | |
| TW202421780A (zh) | T細胞的製造方法 | |
| US20250161367A1 (en) | Therapeutic use of fibroblasts to stimulate regeneration and repair of atrophied spleen | |
| WO2024102777A2 (en) | Compositions and method for expansion of embryonic stem cells | |
| EP2270137A1 (en) | Method for producing cells having characteristic of hematopoietic stem cells/progenitor cells | |
| CN119464288B (zh) | 一种环状rna、过表达载体、构建方法、检测引物和应用 | |
| JP2022513490A (ja) | 遺伝子編集線維芽細胞の治療的使用 | |
| JP2020132592A (ja) | 生体内でドパミン神経細胞を保護する方法 | |
| JP2018201499A (ja) | 安全性と抗炎症作用を高めた間葉系幹細胞 | |
| US20110223138A1 (en) | Mesenchymal stem cells that express increased amounts of anti-apoptotic proteins | |
| WO2024248141A1 (ja) | T前駆細胞の製造方法 | |
| WO2025061158A1 (zh) | 一种表达mcl1的低免疫原性细胞及其制备方法 | |
| WO2025205612A1 (ja) | 制御性細胞の増殖方法 | |
| WO2025264574A1 (en) | Injectable thymus organoids | |
| EP1918366A1 (en) | Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240729 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250113 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250113 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250113 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250114 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20250219 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250219 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260120 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260120 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260423 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260504 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260504 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20260504 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260601 |